{"nctId":"NCT02267135","briefTitle":"Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis","startDateStruct":{"date":"2014-09-29","type":"ACTUAL"},"conditions":["Chronic Scalp Psoriasis"],"count":102,"armGroups":[{"label":"Secukinumab","type":"EXPERIMENTAL","interventionNames":["Biological: Secukinumab 300 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"Secukinumab 300 mg","otherNames":["AIN457 300 mg"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic scalp psoriasis for at least the previous six months\n* Moderate to severe scalp psoriasis as defined by a PSSI score of ≥12 and 30% or higher of scalp surface area affected\n* Must be candidates for systemic therapy, which means having scalp psoriasis inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy.\n\nExclusion Criteria:\n\n* Forms of psoriasis other than chronic plaque\n* Drug-induced psoriasis (e.g., new onset or current exacerbation from β-blockers, calcium channel inhibitors)\n* Ongoing use of prohibited treatments (e.g., topical or systemic corticosteroids, UV therapy)\n* Prior exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL17A or IL-17RA receptors\n* Use of other investigational drugs within 30 days prior to study entry, or within a period of 5 half-lives of the investigational treatment, whichever is longer\n* Active, ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab\n* Active system infections (with the exception of the common cold) during the two weeks prior to starting study treatment\n* Other protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Psoriasis Scalp Severity Index 90 (PSSI 90)","description":"PSSI 90 response (yes) at Week 12; PSSI 90 response means at least a 90% improvement in scalp psoriasis\n\nPercentage of participants with Psoriasis Scalp Severity Index 90 (PSSI 90) response of \"yes\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary: Investigator's Global Assessment Model 2011 (IGA Mod 2011) Score of 0 or 1 (Scalp Only)","description":"IGA mod 2011 score of 0 or 1 (scalp only) response at Week 12 (non-responder imputation); IGA mod 2011 score of 0 means no sign of scalp psoriasis, and IGA score of 1 means almost no scalp psoriasis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PSSI Score","description":"Change from baseline in Psoriasis Scalp Severity Index (PSSI) score. PSSI score ranges from 0-72 with 72 being severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.47","spread":"17.052"},{"groupId":"OG001","value":"-5.98","spread":"12.868"}]}]}]},{"type":"SECONDARY","title":"Psoriasis Scalp Severity Index 75 (PSSI 75) Response","description":"PSSI 75 response (yes) at Week 12 (non-responder imputation); PSSI 75 response means at least a 75% improvement in scalp psoriasis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Psoriasis Scalp Severity Index 100 (PSSI 100) Response","description":"PSSI 100 response (yes) at Week 12 (non-responder imputation); PSSI 100 response means no sign of scalp psoriasis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to 50% Reduction in PSSI Score up to Week 12","description":"Time to 50% reduction in PSSI score up to week 12 was estimated for drug arm\n\nThe median time to reduction was not estimable for placebo because a 50% reduction in PSSI score was not achieved by enough participants receiving placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Psoriasis Area and Severity Index 75 (PASI 75)","description":"PASI 75 response (yes) at Week 12 (non-responder imputation); PASI 75 response means at least a 75% improvement in body psoriasis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Psoriasis Area and Severity Index 90 (PASI 90)","description":"PASI 90 response (yes) at Week 12 (non-responder imputation); PASI 90 response means at least a 90% improvement in body psoriasis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Psoriasis Area and Severity Index 100 (PASI 100)","description":"PASI 100 response (yes) at Week 12 (non-responder imputation); PASI 100 response means no sign of body psoriasis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Global Assessment Model 2011 (GA Mod 2011) Score of 0 or 1 (Entire Body Including Scalp)","description":"IGA mod 2011 score of 0 or 1 (entire body including scalp); IGA mod 2011 score of 0 means no sign of psoriasis, and IGA mod 2011 score of 1 means almost no psoriasis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Subject Assessment of Pain","description":"Change from baseline in the Subject Assessment of Pain\n\nScale of 0-10 with 10 being the most painful","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.43","spread":"3.233"},{"groupId":"OG001","value":"1.04","spread":"2.615"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Subject Assessment of Itching","description":"Change from baseline in the Subject Assessment of Itching\n\nScale of 0-10 with 10 being the most itchy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.10","spread":"3.008"},{"groupId":"OG001","value":"-0.24","spread":"2.840"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Subject Assessment of Scaling (Scalp Only)","description":"Change from baseline in the Subject Assessment of Scaling (scalp only)\n\nScale of 0-10 with 10 being the most scaling","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.24","spread":"2.861"},{"groupId":"OG001","value":"-0.65","spread":"2.763"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":51},"commonTop":["DIARRHOEA","DERMATITIS CONTACT","NASOPHARYNGITIS"]}}}